Drugs / VGX-3400X
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01142362 | Jun 2010 → Nov 2011 | — | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGX-3400X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01142362 ↗ |
| Modality | Vaccine | “The investigators have developed a DNA vaccine, VGX-3400X, which includes plasmids targeting the proteins of the H5N1 avian influenza virus.” NCT01142362 ↗ |
| Route | Intramuscular | “administered by Intramuscular (IM) Injection Followed by Electroporation (EP)” NCT01142362 ↗ |